We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$731M
AUM Growth
-$365M
Cap. Flow
-$340M
Cap. Flow %
-46.53%
Top 10 Hldgs %
45.16%
Holding
128
New
24
Increased
37
Reduced
18
Closed
39

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.5M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.99M
4
VRNT
Verint Systems
VRNT
+$9.95M
5
STOK icon
Stoke Therapeutics
STOK
+$9.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$31.2M
2
NVO
Novo Nordisk
NVO
+$20.9M
3
VTRS icon
Viatris
VTRS
+$13.3M
4
NVS icon
Novartis
NVS
+$9.61M
5
PTCT icon
PTC Therapeutics
PTCT
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 70.2%
2 Technology 11.72%
3 Industrials 2.28%
4 Consumer Discretionary 1.91%
5 Communication Services 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOOGL icon
101
Alphabet (Google) Class A
GOOGL
$4.36T
– –
-100,000
Closed -$5.88M
IMTX icon
102
Immatics
IMTX
$1.18B
– –
-200,000
Closed -$2.07M
MGNX icon
103
MacroGenics
MGNX
$235M
– –
-235,000
Closed -$4.22M
MGTX icon
104
MeiraGTx Holdings
MGTX
$1.09B
– –
-36,159
Closed -$623K
MHK icon
105
Mohawk Industries
MHK
$7.5B
– –
-37,000
Closed -$4.67M
NVO
106
Novo Nordisk
NVO
$208B
– –
-800,000
Closed -$20.9M
NVS icon
107
Novartis
NVS
$297B
– –
-111,600
Closed -$9.61M
PTCT icon
108
PTC Therapeutics
PTCT
$5.68B
– –
-220,500
Closed -$8.3M
XBI icon
109
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-3,335,000
Closed -$302M
XENE icon
110
Xenon Pharmaceuticals
XENE
$6.06B
– –
-533,655
Closed -$5.42M
QTTB icon
111
Q32 Bio
QTTB
$466M
– –
-8,944
Closed -$4.46M
TVRD
112
Tvardi Therapeutics
TVRD
$19.7M
– –
-8,443
Closed -$5.96M
DCPH
113
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-115,033
Closed -$2.67M
CBAY
114
DELISTED
Cymabay Therapeutics
CBAY
– –
-345,535
Closed -$4.59M
ACER
115
DELISTED
Acer Therapeutics Inc
ACER
– –
-50,000
Closed -$1.22M
RVLP
116
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-864,006
Closed -$3.11M
FSTX
117
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-12,754
Closed -$535K
AERI
118
DELISTED
Aerie Pharmaceuticals
AERI
– –
-150,000
Closed -$7.13M
LOGC
119
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
– –
-417,625
Closed -$4.13M
GBT
120
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-80,000
Closed -$4.23M
KDMN
121
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,490,000
Closed -$3.93M
SBBP
122
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-951,600
Closed -$4.74M
CNST
123
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-40,162
Closed -$544K
IMMU
124
DELISTED
Immunomedics Inc
IMMU
– –
-326,660
Closed -$6.28M
MLNX
125
PUT
DELISTED
Mellanox Technologies, Ltd.
MLNX
– –
-38,500
Closed -$4.56M
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2019 Portfolio in Review

As of Q2 2019, Sphera Funds Management held 128 positions worth $731M, down 33% from $1.1B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $340M in Q2 2019, closing 39 positions and reducing 18 holdings. Its most notable exit was Gilead Sciences, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 55% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $9.39M.

  • Sphera Funds Management's largest Q2 2019 buy was Regeneron Pharmaceuticals: 30,000 shares worth $9.39M.
  • Sphera Funds Management added most to Johnson & Johnson in Q2 2019, an estimated $18.7M increase.
  • Sphera Funds Management's biggest Q2 2019 reduction was Viatris, cutting an estimated $13.3M.
  • Sphera Funds Management fully exited Gilead Sciences in Q2 2019, selling an estimated $31.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $731M portfolio in Q2 2019.
  • Sphera Funds Management opened 24 new positions and closed 39 in Q2 2019.
  • Sphera Funds Management's portfolio value fell 33% quarter-over-quarter to $731M.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.